Pharmaceutical formulation comprising 2,3-dimethyl-6-(N,N-dimethylaminoethyl)-6H-indolo-(2,3-B)quinoxaline
AssigneeVironova Herpes AB
InventorsMohammed Homman, Jan Bergman
Life of this patent
Estimating the term…
Abstract
A pharmaceutical composition for topical administration including 2,3-dimethyl-6-(N,N-dimethylaminoethyl)-6H-indolo-(2,3-b)quinoxaline(B-220) or a pharmaceutically acceptable salt thereof in a pharmaceutically acceptable carrier The composition is useful for the treatment of herpes virus infections of the skin or mucous membranes in a mammal subject.
Claims12
A pharmaceutical composition comprising 2,3-dimethyl-6-(N,N-dimethylaminoethyl)-6H-indolo[2,3-b]quinoxaline, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier selected from the group consisting of a phospholipid, white petrolatum, an alcohol, a glycol, and a combination thereof.
A cream, liquid, lotion, gel, spray, foam or ointment comprising 2,3-dimethyl-6-(N,N-dimethylaminoethyl) -6H-indolo[2,3-b]quinoxaline, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier selected from the group consisting of a phospholipid, white petrolatum, an alcohol, a glycol, and a combination thereof.
A patch, stick, spray dispenser, tube or pen comprising 2,3-dimethyl-6-(N,N-dimethylaminoethyl)-6H-indolo[2,3-b]quinoxaline, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier selected from the group consisting of a phospholipid, white petrolatum, an alcohol, a glycol, and a combination thereof.
Dependencies are inferred from the claim text.